Eliquis Regulatory Post Marketing Surveillance (rPMS)

The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about Eliquis in general practice

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Venous Thromboembolism Cardiovascular Diseases Embolism and Thrombosis Thromboembolism Vascular Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Local Institution

Seoul, 110-744, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Signed data release
Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty

Exclusion criteria

Being treated for an indication not approved for the use of Eliquis® in Korea
Is contraindicated for the use of Eliquis® as described in the Korean label

Treatment and study plan

Apixaban

Drug

Other names: Eliquis

Primary outcomes

Number of Adverse Events (AEs) and serious AEs

Time frame: Up to 30 days after last study drug dose

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

Eliquis (Apixaban) Regulatory Post Marketing Surveillance in Clinical Practice for Venous Thromboembolism (VTE) Prevention

Important dates

Study start: 2014
Primary completion: 2015
Study completion: 2015
First posted: Jun 25, 2013
Registry last updated: Feb 8, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed